Skip to main navigation

Skip to Content

Stock
Financials
- SEC Filings
- Financial Reports
News & Events
Corporate Governance
Our Company
IR Resources

Press Releases

Year

Genenta’s CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”

Oct 23, 2024

Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer

Oct 02, 2024

Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

May 06, 2024

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

Feb 08, 2024

Genenta to Present at Upcoming Scientific and Investor Conferences

Sep 06, 2023

Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments

Jul 28, 2023

The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma

Jun 29, 2023

Genenta to Provide Update on Lead Product Temferon™

May 16, 2023

Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing

Apr 26, 2023

Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications

Apr 03, 2023

Pagination

Current page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Next page
Last page

Displaying 1 - 10 of 59

Investor Contact

RSS Feeds

Print

ITALY
Dibit – San Raffaele Hospital
Via Olgettina, 58
20132 Milano

UNITED STATES
LaunchLabs – Alexandria Center
430 East 29th Street
New York NY 10016

PARTNERS

genenta-img-san_raffaele

© 2024 Genenta Science. All rights reserved - - Terms and conditions - Privacy Policy